Ascent Resources’ Colin Hutchinson discusses the results of their PG-10 flow test in this exclusive interview with DirectorsTalk
Zeus Capital’s Dr Tom McColm discusses Ceres Power Holdings plc in this exclusive interview with DirectorsTalk
Deltex Medical Group’s Ewan Phillips discusses the increased range of medical conditions for which South Korea will reimburse the cost of using ODM, what this means for the company, other international markets and whether 2017 will be a good year in this exclusive interview with DirectorsTalk
Ceres Power Holdings’ Phil Caldwell discusses their latest trading update, the opportunities for the business, the effects of Trump and Brexit and expectations for the second half of their financial year in this exclusive interview with DirectorsTalk
ImmuPharma’s Tim McCarthy discusses their Phase III Lupuzor trial; why the completion of patient recruitment on track is important, the significance of the 70 patients dosed in the US, safety profile and its importance, the market potential for Lupuzor if approved and their key milestones for 2017/2018 in this exclusive interview with DirectorsTalk
Northland Capital Partners’ Vadim Alexandre discusses the latest update from ImmuPharma PLC on their Lupuzor Phase III study in this exclusive interview with DirectorsTalk
Defenx’s Philipp Prince discusses their latest trading update, integration of Memopal, channel partners, Café Bazaar and their goals for 2017 in this exclusive interview with DirectorsTalk
Northland Capital Partners’ Vadim Alexandre discusses ImmuPharma PLC in this exclusive interview with DirectorsTalk
Edenville Energy’s Rufus Short discusses the significance of their partnership with Sinohydro Corporation, the progress of the trial mining at the Rukwa project and his thoughts on the next few months of development for the company in this exclusive interview with DirectorsTalk
Toople’s Andy Hollingworth discusses what the company does, the launch of their new cloud business telephony service and why this product is good for their business from an investor point in this exclusive interview with DirectorsTalk
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
